Mariotti Angelo
Department of Periodontology, College of Dentistry, The Ohio State University, Columbus, OH 43210, USA.
J Dent Educ. 2008 Aug;72(8):919-29.
Bisphosphonates are important drugs that are increasingly prescribed to reduce the morbidity associated with osteoclast-mediated bone diseases. Shortly after the turn of the century, a variety of case reports described a necrosis of the jaw bone in patients using bisphosphonates. Currently, an exposed area of necrotic jaw bone present for at least eight weeks in patients using bisphosphonates has been defined as a bisphosphonate-associated osteonecrosis (BON) by the American Dental Association. BON may occur spontaneously but is more frequently associated with local trauma to the jaw. At this time, a causal relationship between BON and bisphosphonates has not been demonstrated. This review will evaluate current data related to the occurrence, risk, prevention, treatment, and management of BON.
双膦酸盐是一类重要药物，越来越多地被用于减少与破骨细胞介导的骨病相关的发病率。在世纪之交后不久，各种病例报告描述了使用双膦酸盐的患者出现颌骨坏死的情况。目前，美国牙科协会已将使用双膦酸盐的患者中存在至少八周的暴露性颌骨坏死区域定义为双膦酸盐相关骨坏死（BON）。BON可能自发发生，但更常与颌骨局部创伤有关。目前，尚未证实BON与双膦酸盐之间存在因果关系。本综述将评估与BON的发生、风险、预防、治疗及管理相关的现有数据。
